PT  - JOURNAL ARTICLE
AU  - Odero, Lydia
AU  - Chafetz, Aaron
AU  - Gikura, Mary
AU  - Goldstein, Deborah
AU  - Golin, Rachel
AU  - Kemunto, Diana
AU  - Maina, Nelly
AU  - Mutisya, Immaculate
AU  - Muthoka, Kennedy
AU  - Nganga, Evelyn
AU  - Okegbe, Tishina
AU  - Okutoyi, Salome
AU  - Omoro, Gonza
AU  - Siberry, George
AU  - Wafula, Rose
AU  - Achwoka, Dunstan
TI  - The Impact of Normal Aging Out on Continuity of Treatment among Children and Adolescents Living with HIV in the PEPFAR Supported Program in Kenya
AID  - 10.1101/2024.01.16.24301354
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.16.24301354
4099  - http://medrxiv.org/content/early/2024/01/17/2024.01.16.24301354.short
4100  - http://medrxiv.org/content/early/2024/01/17/2024.01.16.24301354.full
AB  - Introduction To reduce HIV-related morbidity and mortality among children and adolescents living with HIV, defined as those 0-14 years old, continuity of treatment is critical. Treatment continuity estimates among children and adolescents living with HIV lag adults. We sought to understand how aging out among children and adolescents living with HIV in Kenya impacts continuity of treatment.Methods A retrospective cohort analysis was performed on de-identified individual-level data from the Kenya National Data Warehouse for all clients who initiated and/or received antiretroviral therapy between the periods of Oct 1, 2018 and Sep 30, 2022 (US Government fiscal years 2019-2022). Children and adolescents living with HIV previously on antiretroviral therapy and those newly initiating antiretroviral therapy were included in the analysis. Outcomes included aging out of the cohort after turning 15 years old, interruption in treatment, return to treatment, and remaining active on treatment.Results The study analyzed client-level data for four US Government fiscal years 2019-2022. The number of active children and adolescents living with HIV on treatment at the end of fiscal year 2019 was 44,628. This changed to 48,218, 48,262, and 44,780 representing 8%, 0%, and -7% cohort growth/loss at the end of fiscal years 2020, 2021 and 2022, respectively. Among those who were on treatment at the beginning of each fiscal year, aging-out accounted for 47%, 39%, and 28% of the total losses for the periods 2020, 2021 and 2022, respectively. Interruptions in treatment accounted for proportions ranging from 5-9% among those active on treatment. Among the newly-initiated on treatment within each fiscal year, aging-out proportions ranged from 3%-5%. Among those who returned to treatment in each fiscal year, the proportions who remained active at the end of the fiscal year varied from 72%-76%.Conclusions This analysis suggests that normal aging-out results in underestimation of HIV treatment continuity for children and adolescents living with HIV. Routine aging out analyses can inform programs on their true rates of interruptions in treatment, as they work to achieve epidemic control among children and adolescents living with HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis article was made possible by the support of the American people through the United States Agency for International Development under the U.S. President's Emergency Plan for AIDS Relief.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was approved by Jomo Kenyatta University of Agriculture and Technology, Ethics and Research Committee (JKU/ISERC/02316/0880) Office of the Associate Director for Science, Centers for Disease Control and Prevention (CDC) with Accession #: CGH-KEN-1/18/23-8faf7 and research license obtained from the National Commission for Science, Technology & Innovation (NACOSTI/P/23/27455). Client’s consent was not required as the authors neither interacted with the clients nor had access to identifiable data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are openly available in the Kenya National Data Warehouse at https://dwh.nascop.org/#/ https://dwh.nascop.org/#/